

OPIE

Please type a plus sign (+) inside this box → +

DEU 1 10 2002

(Modified) PTO/SB/21 (6-98)  
Approved for use through 09/30/2000. OMB 0651-0031  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

# TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

Total Number of Pages in This Submission

4 +

Application Number

10/084,706

Filing Date

February 26, 2002

First Named Inventor

Rasmussen, et al

Group Art Unit

1647

Examiner Name

J. Seharaseyon

RECEIVED

DEC 1 2 2002

TECH CENTER 1600/2900

Attorney Docket Number

0228us410

## ENCLOSURES (check all that apply)

<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Assignment Papers (for an Application)	<input type="checkbox"/> After Allowance Communication to Group
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Amendment / Response	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition Routing Slip (PTO/SB/69) and Accompanying Petition	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address	<input checked="" type="checkbox"/> Additional Enclosure(s) (please identify below):
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Terminal Disclaimer	<input type="checkbox"/> PTO/SB/08A-B; cited references (4); return postcard
<input checked="" type="checkbox"/> Supplemental Information Disclosure Statement	<input type="checkbox"/> Small Entity Statement	
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> Request for Refund	
<input type="checkbox"/> Response to Missing Parts/ Incomplete Application		
<input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53		
<p><b>Authorization to Charge Deposit Account</b>            Please charge Deposit Account No. 50-0990 for any additional fees associated with this paper or during the pendency of this application, including any extensions of time for consideration of the documents enclosed.</p>		
Remarks		

## SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm or Individual name

Joanne R. Petithory, Reg. No. 42,995  
Maxygen, Inc.

Signature

Date

December 6, 2002

## CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to Assistant Commissioner for Patents, Washington, D.C. 20231 on this date

Typed or printed name

Julie K. Mausen

Signature

Date



I hereby certify that this correspondence is  
being deposited with the United States  
Postal Service as first class mail in an envelope addressed to:  
Assistant Commissioner for Patents  
Washington, D.C. 20231

On December 6, 2002

  
Julie K. Mausen

RECEIVED

DEC 12 2002

TECH CENTER 1600/2900

Attorney Docket No. 0228us410

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Rasmussen, et al.

Examiner: J. Seharaseyon

Application No.: 10/084,706

Art Unit: 1647

Filed: February 26, 2002

SUPPLEMENTAL INFORMATION  
DISCLOSURE STATEMENT UNDER  
37 CFR § 1.97 and §1.98

For: NEW INTERFERON  
BETA-LIKE MOLECULES

Assistant Commissioner for Patents  
Washington, D.C. 20231


Sir:

The references cited on attached form PTO-SB/08 are being called to the attention of the Examiner. Copies of the references are enclosed. It is respectfully requested that the cited information be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

As provided for by 37 CFR 1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.

Applicants believe that no fee is required for submission of this statement, since it is being submitted prior to the first Office Action on the merits. However, if a fee is required, the Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No. 50-0990. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,



Joanne R. Petithory  
Reg. No. 42,995

Maxygen, Inc.  
Patent Department  
515 Galveston Drive  
Redwood City, CA 94063  
Telephone: (650) 298-5300  
Facsimile: (650) 298-5446  
Customer No.: 30560

<p>Substitute for form 1449A-B/PTO</p> <p><b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b></p> <p><i>(use as many sheets as necessary)</i></p>	<p>Complete if Known</p> <table border="0"> <tr> <td>Application Number</td> <td><b>10/084,706</b></td> </tr> <tr> <td>Filing Date</td> <td><b>February 26, 2002</b></td> </tr> <tr> <td>First Named Inventor</td> <td><b>Rasmussen, et al.</b></td> </tr> <tr> <td>Group Art Unit</td> <td><b>1647</b></td> </tr> <tr> <td>Examiner Name</td> <td><b>J. Seharasey翁</b></td> </tr> <tr> <td>Attorney Docket Number</td> <td><b>0228us410</b></td> </tr> </table>	Application Number	<b>10/084,706</b>	Filing Date	<b>February 26, 2002</b>	First Named Inventor	<b>Rasmussen, et al.</b>	Group Art Unit	<b>1647</b>	Examiner Name	<b>J. Seharasey翁</b>	Attorney Docket Number	<b>0228us410</b>
Application Number	<b>10/084,706</b>												
Filing Date	<b>February 26, 2002</b>												
First Named Inventor	<b>Rasmussen, et al.</b>												
Group Art Unit	<b>1647</b>												
Examiner Name	<b>J. Seharasey翁</b>												
Attorney Docket Number	<b>0228us410</b>												

RECEIVED

DEC 12 2007

~~TECH CENTER 1600,2900~~

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T
	4	O'CONNELL, et al., "The Influence of Flanking Sequences on O-Glycosylation", <i>Biochemical and Biophysical Research Communications</i> , 1991, pp. 1024-1030, 180:2.	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

**\*EXAMINER:** Initial if reference considered whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.